Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Treating platinum resistant ovarian cancer

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.12
Views: 6025

Dr Andres Poveda – Fundacion Instituto Valenciano de Oncologia, Spain

Dr Andres Poveda talks to ecancer at the 2012 ESMO meeting about the treatment of platinum resistant ovarian cancer.  


Tivantinib is now used to increase progression free survival in clinical trials with positive early results.  Results offer hope to patients in the worst condition. Previously patients with high resistance to treatments were treated mainly in the palliative setting.


Bevacizumab has been also added to treatments with the potential of doubling progression free survival. This breakthrough is set to increase quality of life and reduce symptoms as well. 


Filming supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation